Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zephrex-D Solo Show In W.Va. Could Move Tamper-Resistant PSE To Starring Role

This article was originally published in The Tan Sheet

Executive Summary

With CVS selling only Zephrex-D at its W.Va. stores, Walgreens planning to make a similar change and pseudoephedrine diversion to make meth also a problem in other states, other manufacturers of single-ingredient PSE products could feel pressure to start using tamper-resistant formulations.

You may also be interested in...



PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach

Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.

Tamper-Resistant Pseudoephedrine Sparks Pharmacies’ Interest

Ohio and West Virginia chain Fruth Pharmacy begins replacing the 30 mg PSE products available in its stores with Acura Pharmaceuticals’ Nexafed product. Meanwhile, DEA says Westport Pharmaceuticals should not make an extraction-proof claim for its Zephrex-D PSE product.

Qualifying Suppliers For US Supplement Ingredient Identity Requirement Still An Option With Thorns

Failing to qualify suppliers “one of the more common citations” FDA inspectors find at supplement facilities, says ORA deputy director Michael Dutcher. “If you're not sort of reconfirming once in a while it could lead to a problem with your products that you weren't even expecting.”

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS107021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel